The brain consequences of systemic inflammation were not fully alleviated by ibuprofen treatment in mice.
Amyloid beta-Peptides
/ metabolism
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Anxiety
/ prevention & control
Behavior, Animal
/ drug effects
Brain
/ physiopathology
Cytokines
/ metabolism
Depression
/ prevention & control
Encephalitis
/ chemically induced
Ibuprofen
/ therapeutic use
Inflammation
/ chemically induced
Lipopolysaccharides
Male
Malondialdehyde
/ metabolism
Memory Disorders
/ prevention & control
Mice
Mice, Inbred BALB C
Morris Water Maze Test
Peptide Fragments
/ metabolism
Psychomotor Performance
/ drug effects
Recognition, Psychology
/ drug effects
Swimming
/ psychology
Anxiety
Chronic inflammation
Depression
Memory dysfunction
NSAIDs
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
13
03
2020
accepted:
15
07
2020
revised:
13
07
2020
pubmed:
23
7
2020
medline:
9
9
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Extensive data point to the immune system as an important factor underlying the pathogenesis of brain diseases. Epidemiological studies have shown that long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) significantly reduces the onset and progression of Alzheimer's disease. The present study aimed to investigate whether ibuprofen (IBU) is able to prevent the long-lasting alterations of brain function induced by systemic inflammation. Mice received intraperitoneal injections of lipopolysaccharide (LPS; 250 µg/kg/day) for seven consecutive days. Ibuprofen administration (40 mg/kg/day) was started three days before the LPS injections and continued until the last day of LPS injection. Within the next 2 weeks, mice performances on the behavioral tests were evaluated, and then brain tissue samples for biochemical analyses were collected. The findings showed that ibuprofen significantly improved mice's performance in the passive avoidance test and reduced anxiety- and depressive-like behaviors. However, ibuprofen could not significantly improve spatial memory in the Morris water maze test and recognition ability in the novel object recognition test. TNF-α and IL-1β cytokines levels and malondialdehyde (MDA) concentration in the hippocampal tissues of LPS-treated mice were significantly lowered by ibuprofen treatment, whereas no significant effects on IL-10 production and hippocampal BDNF levels were observed. In addition, ibuprofen did not significantly reduce amyloid-β Overall, the findings of the present study suggest that some, but not all, of the adverse effects of systemic inflammation are alleviated by ibuprofen treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Extensive data point to the immune system as an important factor underlying the pathogenesis of brain diseases. Epidemiological studies have shown that long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) significantly reduces the onset and progression of Alzheimer's disease. The present study aimed to investigate whether ibuprofen (IBU) is able to prevent the long-lasting alterations of brain function induced by systemic inflammation.
METHODS
METHODS
Mice received intraperitoneal injections of lipopolysaccharide (LPS; 250 µg/kg/day) for seven consecutive days. Ibuprofen administration (40 mg/kg/day) was started three days before the LPS injections and continued until the last day of LPS injection. Within the next 2 weeks, mice performances on the behavioral tests were evaluated, and then brain tissue samples for biochemical analyses were collected.
RESULTS
RESULTS
The findings showed that ibuprofen significantly improved mice's performance in the passive avoidance test and reduced anxiety- and depressive-like behaviors. However, ibuprofen could not significantly improve spatial memory in the Morris water maze test and recognition ability in the novel object recognition test. TNF-α and IL-1β cytokines levels and malondialdehyde (MDA) concentration in the hippocampal tissues of LPS-treated mice were significantly lowered by ibuprofen treatment, whereas no significant effects on IL-10 production and hippocampal BDNF levels were observed. In addition, ibuprofen did not significantly reduce amyloid-β
CONCLUSION
CONCLUSIONS
Overall, the findings of the present study suggest that some, but not all, of the adverse effects of systemic inflammation are alleviated by ibuprofen treatment.
Identifiants
pubmed: 32696348
doi: 10.1007/s43440-020-00141-y
pii: 10.1007/s43440-020-00141-y
doi:
Substances chimiques
Amyloid beta-Peptides
0
Anti-Inflammatory Agents, Non-Steroidal
0
Cytokines
0
Lipopolysaccharides
0
Peptide Fragments
0
amyloid beta-protein (1-40)
0
Malondialdehyde
4Y8F71G49Q
Ibuprofen
WK2XYI10QM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-142Subventions
Organisme : National Institute for Medical Research Development
ID : 982737
Références
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2015;16:22.
doi: 10.1038/nri.2015.5
Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16:229–36.
pubmed: 25689443
doi: 10.1038/ni.3102
Shastri A, Bonifati DM, Kishore U. Innate immunity and neuroinflammation. Mediat Inflamm. 2013;2013:1–19.
doi: 10.1155/2013/342931
Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010;120:277–86.
pubmed: 20644946
doi: 10.1007/s00401-010-0722-x
Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440–6.
pubmed: 11826421
doi: 10.1053/jhep.2002.31257
Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–9.
pubmed: 11826420
doi: 10.1053/jhep.2002.30688
Salmani H, Hosseini M, Baghcheghi Y, Moradi-Marjaneh R, Mokhtari-Zaer A. Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: the role of PPAR-gamma activation. Cytokine. 2020;125:154860.
pubmed: 31574424
doi: 10.1016/j.cyto.2019.154860
Lee YJ, Choi DY, Choi IS, Kim KH, Kim YH, Kim HM, et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflamm. 2012;9:35.
McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639–47.
pubmed: 16697488
doi: 10.1016/j.neurobiolaging.2006.03.013
Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci. 2007;28:536–43.
pubmed: 17900710
doi: 10.1016/j.tips.2007.09.004
Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70:1672–7.
pubmed: 18458226
pmcid: 2758242
doi: 10.1212/01.wnl.0000311269.57716.63
Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Rotterdam Study Neurol. 1995;45:1441–5.
In’T Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515–21.
doi: 10.1056/NEJMoa010178
McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008;1207:225–36.
pubmed: 18374906
pmcid: 2587244
doi: 10.1016/j.brainres.2008.01.095
Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, et al. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology. 2005;30:1111–20.
pubmed: 15688088
doi: 10.1038/sj.npp.1300668
pmcid: 15688088
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain. 2005;128:1442–533.
pubmed: 15817521
doi: 10.1093/brain/awh452
pmcid: 15817521
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709–14.
pubmed: 10908610
pmcid: 6772529
doi: 10.1523/JNEUROSCI.20-15-05709.2000
Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53:197–207.
pubmed: 10408559
doi: 10.1212/WNL.53.1.197
pmcid: 10408559
Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66–71.
pubmed: 14718699
doi: 10.1212/WNL.62.1.66
pmcid: 14718699
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819–26.
pubmed: 12783912
doi: 10.1001/jama.289.21.2819
Cunningham C, Skelly DT. Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol. 2012;7:60–73.
pubmed: 21932048
doi: 10.1007/s11481-011-9312-5
Rainsford KD. Ibuprofen: from invention to an OTC therapeutic mainstay. Int J Clin Pract Suppl. 2013;67:9–20.
doi: 10.1111/ijcp.12055
Hedayati Moghadam M, Rezaee SAR, Hosseini M, Niazmand S, Salmani H, Rafatpanah H, et al. HTLV-1 infection-induced motor dysfunction, memory impairment, depression, and brain tissues oxidative damage in female BALB/c mice. Life Sci. 2018;212:9–19.
pubmed: 30248348
doi: 10.1016/j.lfs.2018.09.031
Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc. 2006;1:122–4.
pubmed: 17406223
doi: 10.1038/nprot.2006.20
Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp. 2012;59:e3638.
Baghcheghi Y, Hosseini M, Beheshti F, Salmani H, Anaeigoudari A. Thymoquinone reverses learning and memory impairments and brain tissue oxidative damage in hypothyroid juvenile rats. Arq Neuropsiquiatr. 2018;76:32–40.
pubmed: 29364392
doi: 10.1590/0004-282x20170182
Salmani H, Hosseini M, Beheshti F, Baghcheghi Y, Sadeghnia HR, Soukhtanloo M, et al. Angiotensin receptor blocker, losartan ameliorates neuroinflammation and behavioral consequences of lipopolysaccharide injection. Life Sci. 2018;203:161–70.
pubmed: 29684446
doi: 10.1016/j.lfs.2018.04.033
Gonzalez H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol. 2014;274:1–13.
pubmed: 25091432
doi: 10.1016/j.jneuroim.2014.07.012
Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141–54.
pubmed: 25981208
doi: 10.1016/j.neuroscience.2015.05.018
Llorens-Martin M, Jurado-Arjona J, Fuster-Matanzo A, Hernandez F, Rabano A, Avila J. Peripherally triggered and GSK-3beta-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. Transl Psychiatry. 2014;4:e463.
pubmed: 25313506
pmcid: 4350524
doi: 10.1038/tp.2014.92
Norden DM, McCarthy DO, Bicer S, Devine RD, Reiser PJ, Godbout JP, et al. Ibuprofen ameliorates fatigue- and depressive-like behavior in tumor-bearing mice. Life Sci. 2015;143:65–70.
pubmed: 26498217
pmcid: 4679603
doi: 10.1016/j.lfs.2015.10.020
Felger JC. Imaging the role of inflammation in mood and anxiety-related disorders. Curr Neuropharmacol. 2018;16:533–58.
pubmed: 29173175
pmcid: 5997866
doi: 10.2174/1570159X15666171123201142
Anderson ST, Commins S, Moynagh PN, Coogan AN. Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse. Brain Behav Immun. 2015;43:98–109.
pubmed: 25063709
doi: 10.1016/j.bbi.2014.07.007
pmcid: 25063709
Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013;38:1609–16.
pubmed: 23511700
pmcid: 3717543
doi: 10.1038/npp.2013.71
Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39:19–34.
pubmed: 23039106
pmcid: 3553257
doi: 10.1111/j.1365-2990.2012.01306.x
Dong Z, Yan L, Huang G, Zhang L, Mei B, Meng B. Ibuprofen partially attenuates neurodegenerative symptoms in presenilin conditional double-knockout mice. Neuroscience. 2014;270:58–68.
pubmed: 24699228
doi: 10.1016/j.neuroscience.2014.03.048
pmcid: 24699228
Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, et al. Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain. 2008;131:651–64.
pubmed: 18292081
pmcid: 2628581
doi: 10.1093/brain/awn008
Browne KD, Iwata A, Putt ME, Smith DH. Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats. Exp Neurol. 2006;201:301–7.
pubmed: 16764859
doi: 10.1016/j.expneurol.2006.04.008
pmcid: 16764859
Shaw KN, Commins S, O'Mara SM. Cyclooxygenase inhibition attenuates endotoxin-induced spatial learning deficits, but not an endotoxin-induced blockade of long-term potentiation. Brain Res. 2005;1038:231–7.
pubmed: 15757639
doi: 10.1016/j.brainres.2005.01.035
pmcid: 15757639
Kim JJ, Jung MW. Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. Neurosci Biobehav Rev. 2006;30:188–202.
pubmed: 16120461
doi: 10.1016/j.neubiorev.2005.06.005
Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry. 2007;12:656–70.
pubmed: 17264839
pmcid: 2442923
doi: 10.1038/sj.mp.4001957
Lim SL, Rodriguez-Ortiz CJ, Kitazawa M. Infection, systemic inflammation, and Alzheimer's disease. Microbes Infect. 2015;17:549–56.
pubmed: 25912134
doi: 10.1016/j.micinf.2015.04.004
Carret-Rebillat AS, Pace C, Gourmaud S, Ravasi L, Montagne-Stora S, Longueville S, et al. Neuroinflammation and Abeta accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation. Sci Rep. 2015;5:8489.
pubmed: 25687824
pmcid: 4330547
doi: 10.1038/srep08489
Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007;282:22707–20.
pubmed: 17556372
pmcid: 4435736
doi: 10.1074/jbc.M611050200
Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci. 2010;2:19.
pubmed: 20725517
pmcid: 2912027
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212–6.
pubmed: 11700559
doi: 10.1038/35102591
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23:9796–804.
pubmed: 14586007
pmcid: 6740896
doi: 10.1523/JNEUROSCI.23-30-09796.2003